201 related articles for article (PubMed ID: 16524323)
21. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
22. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
23. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
Lee N; Authier S; Pugsley MK; Curtis MJ
Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
[TBL] [Abstract][Full Text] [Related]
24. Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation.
Lu HR; Vlaminckx E; Gallacher DJ
J Pharmacol Toxicol Methods; 2008; 57(1):1-8. PubMed ID: 17964190
[TBL] [Abstract][Full Text] [Related]
25. The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaine-induced cardiac effects.
Goineau S; Castagné V; Guillaume P; Froget G
J Pharmacol Toxicol Methods; 2012 Jul; 66(1):52-8. PubMed ID: 22691624
[TBL] [Abstract][Full Text] [Related]
26. A step towards characterisation of electrophysiological profile of torsadogenic drugs.
Champeroux P; Ouillé A; Martel E; Fowler JS; Maurin A; Richard S; Le Guennec JY
J Pharmacol Toxicol Methods; 2011; 63(3):269-78. PubMed ID: 21224008
[TBL] [Abstract][Full Text] [Related]
27. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.
Puisieux FL; Adamantidis MM; Dumotier BM; Dupuis BA
Br J Pharmacol; 1996 Apr; 117(7):1377-9. PubMed ID: 8730728
[TBL] [Abstract][Full Text] [Related]
28. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
Guo L; Dong Z; Guthrie H
J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
[TBL] [Abstract][Full Text] [Related]
29. Predicting drug-induced QT prolongation and torsades de pointes: a review of preclinical endpoint measures.
Townsend C; Brown BS
Curr Protoc Pharmacol; 2013 Jun; Chapter 10():Unit 10.16. PubMed ID: 23744708
[TBL] [Abstract][Full Text] [Related]
30. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
Tabo M; Kimura K; Ito S
J Pharmacol Toxicol Methods; 2007; 55(3):254-61. PubMed ID: 17229580
[TBL] [Abstract][Full Text] [Related]
31. Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance.
Adamantidis MM; Lacroix DL; Caron JF; Dupuis BA
J Cardiovasc Pharmacol; 1995 Aug; 26(2):319-27. PubMed ID: 7475058
[TBL] [Abstract][Full Text] [Related]
32. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists.
Gilbert JD; Cahill SA; McCartney DG; Lukas A; Gross GJ
Can J Physiol Pharmacol; 2000 May; 78(5):407-14. PubMed ID: 10841436
[TBL] [Abstract][Full Text] [Related]
33. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
Johansson M; Carlsson L
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
[TBL] [Abstract][Full Text] [Related]
34. Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.
Detre E; Thomsen MB; Beekman JD; Petersen KU; Vos MA
Br J Pharmacol; 2005 Jun; 145(3):397-404. PubMed ID: 15778734
[TBL] [Abstract][Full Text] [Related]
35. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres.
Abi-Gerges N; Small BG; Lawrence CL; Hammond TG; Valentin JP; Pollard CE
Br J Pharmacol; 2004 Aug; 142(8):1255-64. PubMed ID: 15265803
[TBL] [Abstract][Full Text] [Related]
36. An overview of QT interval assessment in safety pharmacology.
Lacroix P; Picard S
Curr Protoc Pharmacol; 2006 Jul; Chapter 10():Unit10.7. PubMed ID: 22294169
[TBL] [Abstract][Full Text] [Related]
37. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
Singh BN; Wadhani N
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
[TBL] [Abstract][Full Text] [Related]
38. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
Guns PJ; Johnson DM; Weltens E; Lissens J
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
[TBL] [Abstract][Full Text] [Related]
39. How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model.
Liu G; Liu T; Cohen D; Liu T; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():161-70. PubMed ID: 27195944
[TBL] [Abstract][Full Text] [Related]
40. Disturbances of cardiac wavelength and repolarization precede Torsade de Pointes and ventricular fibrillation in Langendorff perfused rabbit hearts.
Hondeghem LM
Prog Biophys Mol Biol; 2016 May; 121(1):3-10. PubMed ID: 26980523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
